CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer

References

• Shen H, Shen J, Wang L, et al. Low miR-145 expression level is associated with poor pathological differentiation and poor prognosis in non-small cell lung cancer. Biomed Pharmacother 2015;69:301-5
   PubMed Web of Science ®Google Scholar
• Mah TL, Yap XN, Limviphuvadh V, et al. Novel SNP improves differential survivability and mortality in non-small cell lung cancer patients. BMC Genomics 2014;15(Suppl 9):S20
   PubMedGoogle Scholar
• Tan F, Shi Y, Wang Y, et al. Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer. Future Oncol 2015;11(3):385-97
   PubMed Web of Science ®Google Scholar
• O’Mahony S, Nathan S, Mohajer R, et al. Survival Prediction in Ambulatory Patients With Stage III/IV Non-Small Cell Lung Cancer Using the Palliative Performance Scale, ECOG, and Lung Cancer Symptom Scale. Am J Hosp Palliat Care 2015. [Epub ahead of print]
   Google Scholar
• Davis KL, Goyal RK, Able SL, et al. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer. Lung Cancer 2015;87(2):176-85
   PubMed Web of Science ®Google Scholar
• Jiang T, Zhou C. Treatment of patients with ALK Gene rearranged non-small cell lung cancer after resistance to crizotinib. Zhongguo Fei Ai Za Zhi 2015;18(2):69-74
   PubMedGoogle Scholar
• Iacono D, Chiari R, Metro G, et al. Future options for ALK-positive non-small cell lung cancer. Lung Cancer 2015;87(3):211-19
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Moro-Sibilot D, Gautschi O, et al. Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. Lung Cancer 2015;87(2):89-95
   PubMed Web of Science ®Google Scholar
• Massarelli E, Papadimitrakopoulou V. Ceritinib for the treatment of late-stage (metastatic) non-small cell lung cancer. Clin Cancer Res 2015;21(4):670-4
   PubMed Web of Science ®Google Scholar
• Jorge SE, Kobayashi SS, Costa DB. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz J Med Biol Res 2014;47(11):929-39
   PubMed Web of Science ®Google Scholar
• Liao BC, Lin CC, Yang JC. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol 2015;27(2):94-101
   PubMed Web of Science ®Google Scholar
• Landi L, Cappuzzo F. Pharmacotherapy targeting the EGFR oncogene in NSCLC. Expert Opin Pharmacother 2014;15(16):2293-305
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013;31(23):2895-902
   PubMed Web of Science ®Google Scholar
• Greenhalgh J, McLeod C, Bagust A, et al. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol Assess 2010;14(Suppl 2):33-9
   PubMed Web of Science ®Google Scholar
• Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27(4):591-8
   PubMed Web of Science ®Google Scholar
• Wu YL, Kim JH, Park K, et al. Efficacy and safety of maintenance erlotinib in Asian patients with advanced non-small-cell lung cancer: a subanalysis of the phase III, randomized SATURN study. Lung Cancer 2012;77(2):339-45
   PubMed Web of Science ®Google Scholar
• Al-Farsi A, Ellis PM. Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line. Front Oncol 2014;4:157
   PubMedGoogle Scholar
• Pirker R, Pereira JR, Szczesna A, et al. FLEX Study TeamCetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373(9674):1525-31
   PubMed Web of Science ®Google Scholar
• Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13(1):33-42
   PubMed Web of Science ®Google Scholar
• Pillai RN, Ramalingam SS. Advances in the diagnosis and treatment of non-small cell lung cancer. Mol Cancer Ther 2014;13(3):557-64
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Mezger J, Ciuleanu TE, et al. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol 2015;16(3):328-37
   PubMed Web of Science ®Google Scholar
• Sacco PC, Maione P, Rossi A, et al. Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer. Expert Rev Respir Med 2015;1-10
   Google Scholar
• Sivendran S, Glodny B, Pan M, et al. Melanoma immunotherapy. Mt Sinai J Med 2010;77(6):620-42
   PubMed Web of Science ®Google Scholar
• Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Curr Opin Immunol 2015;33C:23-35
   Web of Science ®Google Scholar
• Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med 2014;7:357-65
   PubMedGoogle Scholar
• Weber JS. Current perspectives on immunotherapy. Semin Oncol. 2014;41(Suppl 5):S14-29
   Google Scholar
• Rini B. Future approaches in immunotherapy. Semin Oncol. 2014;41(Suppl 5):S30-40
   Google Scholar
• Rijavec E, Genova C, Barletta G, et al. Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. Expert Opin Biol Ther 2014;14(7):1007-17
   PubMed Web of Science ®Google Scholar
• Yoon SH. Immunotherapy for non-small cell lung cancer. Tuberc Respir Dis (Seoul) 2014;77(3):111-15
   Google Scholar
• Domingues D, Turner A, Silva MD, et al. Immunotherapy and lung cancer: current developments and novel targeted therapies. Immunotherapy 2014;6(11):1221-35
   PubMed Web of Science ®Google Scholar
• Reiss KA, Forde PM, Brahmer JR. Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy. Immunotherapy 2014;6(4):459-75
   PubMed Web of Science ®Google Scholar
• Johnson DB, Rioth MJ, Horn L. Immune checkpoint inhibitors in NSCLC. Curr Treat Options Oncol 2014;15(4):658-69
   PubMed Web of Science ®Google Scholar
• Harshman LC, Drake CG, Wargo JA, et al. Cancer Immunotherapy Highlights from the 2014 ASCO Meeting Cancer Immunol Res 2014;2(8):714-19
   Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015;373(2):123-35
   PubMed Web of Science ®Google Scholar
• Liu JK. Anti-cancer vaccines - a one-hit wonder? Yale J Biol Med 2014;87(4):481-9
   PubMedGoogle Scholar
• Singh BH, Gulley JL. Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Ther Adv Vaccines 2014;2(5):137-48
   Google Scholar
• Weber JS. Current perspectives on immunotherapy. Semin Oncol. 2014;41(Suppl 5):S14-29
   Google Scholar
• Bogart JA, Gajra A. Immunotherapy in non-small-cell lung cancer: a good start? Lancet Oncol 2014;15(1):5-6
   PubMed Web of Science ®Google Scholar
• Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15(1):59-68
   PubMed Web of Science ®Google Scholar
• Ruiz R, Hunis B, Raez LE. Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines. Curr Oncol Rep 2014;16(9):400
   PubMed Web of Science ®Google Scholar
• Cuppens K, Vansteenkiste J. Vaccination therapy for non-small-cell lung cancer. Curr Opin Oncol 2014;26(2):165-70
   PubMed Web of Science ®Google Scholar
• Domingues D, Turner A, Silva MD, et al. Immunotherapy and lung cancer: current developments and novel targeted therapies. Immunotherapy 2014;6(11):1221-35
   PubMed Web of Science ®Google Scholar
• Alfonso S, Valdés-Zayas A, Santiesteban E, et al. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 2014;20(14):3660-71
   PubMed Web of Science ®Google Scholar
• Hernández AM, Vázquez AM. Racotumomab-alum vaccine for the treatment of non-small-cell lung cancer. Expert Rev Vaccines 2015;14(1):9-20
   PubMed Web of Science ®Google Scholar
• Gonzalez G, Montero E, Leon K, et al. Autoimmunization to epidermal growth factor, a component of the immunological homunculus. Autoimmun Rev 2002;1(1-2):89-95
   PubMedGoogle Scholar
• González G, Lage A. Cancer vaccines for hormone/growth factor immune deprivation: a feasible approach for cancer treatment. Curr Cancer Drug Targets 2007;7(3):229-41
   PubMed Web of Science ®Google Scholar
• Lage A, Crombet T, González G. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology. Ann Med 2003;35(5):327-36
   PubMed Web of Science ®Google Scholar
• Mancebo A, Casacó A, González B, et al. Repeated dose intramuscular injection of the CIMAvax-EGF vaccine in Sprague Dawley rats induces local and systemic toxicity. Vaccine 2012;30(22):3329-38
   PubMed Web of Science ®Google Scholar
• González G, Crombet T, Catalá M, et al. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 1998;9(4):431-5
   PubMed Web of Science ®Google Scholar
• Gonzalez G, Crombet T, Torres F, et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 2003;14(3):461-6
   PubMed Web of Science ®Google Scholar
• Ramos TC, Vinageras EN, Ferrer MC, et al. Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial. Cancer Biol Ther 2006;5(2):145-9
   PubMed Web of Science ®Google Scholar
• Neninger E, Verdecia BG, Crombet T, et al. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J Immunother 2009;32(1):92-8
   PubMed Web of Science ®Google Scholar
• García B, Neninger E, de la Torre A, et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 2008;14(3):840-6
   PubMed Web of Science ®Google Scholar
• Neninger E, de la Torre A, Osorio M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 2008;26(9):1452-9
   PubMed Web of Science ®Google Scholar
• Crombet T, Neninger E, Acosta S, et al. EGF-based cancer vaccine for advanced NSCLC: Results from a phase III trial. J Clin Oncol 2012;30; Suppl; abstr 2527
   Google Scholar
• Crombet T, Neninger E, Gonzalez J, et al. EGF-based cancer vaccine: Optimizing predictive and surrogate biomarkers. J Clin Oncol 2013;31; Suppl; abstr 3013
   Web of Science ®Google Scholar
• Jorge SE, Kobayashi SS, Costa DB. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz J Med Biol Res 2014;47(11):929-39
   PubMed Web of Science ®Google Scholar
• Cress WD, Chiappori A, Santiago P, et al. Lung cancer mutations and use of targeted agents in Hispanics. Rev Recent Clin Trials 2014;9(4):225-32
   PubMedGoogle Scholar
• Troiani T, Martinelli E, Napolitano S, et al. Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells. Clin Cancer Res 2013;19(24):6751-65
   PubMed Web of Science ®Google Scholar
• Lin C, Chen X, Li M, et al. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma. Clin Lung Cancer 2015. [Epub ahead of print]
   Google Scholar